End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.14 MYR | -1.88% | -7.10% | +16.30% |
May. 22 | Hartalega Turns to Profit in Fiscal Q4 as Revenue Improves | MT |
May. 21 | Hartalega Holdings Berhad announces re-designation of Dato' Razman Hafidz Bin Abu Zarim as Non-Independent Director | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 175.81 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.61 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.30% | 2.28B | B | ||
+6.84% | 26.97B | B+ | ||
-40.08% | 2.67B | B- | ||
-19.95% | 2.4B | C+ | ||
+7.28% | 2.24B | - | A- | |
+16.67% | 1.79B | B | ||
-13.56% | 1.82B | - | ||
+18.92% | 1.26B | B | ||
+20.00% | 1.2B | C | ||
-5.27% | 1.21B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HARTA Stock
- Ratings Hartalega Holdings